Casgevy access in India

Quick orientation

Casgevy is the first CRISPR/Cas9 gene-edited cell therapy approved anywhere in the world, indicated for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in patients aged 12 and older. India is, by burden, one of the most relevant countries on the planet for this therapy. SCD prevalence is concentrated in central, eastern, and tribal populations, and India is often described as the thalassemia capital of the world. Casgevy is not currently registered with the Central Drugs Standard Control Organization (CDSCO). For Indian families, this means the access conversation has two halves: a cross-border treating-center introduction at a qualified Authorized Treatment Center abroad, with any India-side import or ancillary materials handled through Rule 36 of the Drugs and Cosmetics Rules 1945. Reserve Meds coordinates the US-side sourcing, the documentation kit, and the family-side logistics. Reserved for you.

Why patients in India need Casgevy via NPP

India carries one of the largest absolute populations of sickle cell disease and beta-thalassemia patients in the world. SCD prevalence is concentrated in tribal communities across Chhattisgarh, Odisha, Jharkhand, Madhya Pradesh, Maharashtra, and Gujarat, with national programme estimates running into the hundreds of thousands of affected individuals. Beta-thalassemia carrier prevalence is high across the subcontinent, with thousands of transfusion-dependent children identified each year. For a family whose child has severe recurrent vaso-occlusive crises or lifelong transfusion dependence and iron chelation, a one-time potentially disease-modifying therapy is clinically compelling.

Casgevy is not registered with CDSCO as of this page's last review. India's tertiary cell-therapy infrastructure is developing rapidly. CMC Vellore has a long-standing hematopoietic stem cell transplant programme. Tata Memorial Centre runs one of the largest BMT and cell-therapy footprints in the country. AIIMS Delhi has Centre of Excellence designation under the National Policy for Rare Diseases. Even with these capabilities, Casgevy itself is a patient-specific autologous product manufactured by Vertex at a single US facility, with cells shipped manufacturer-direct to a qualified Authorized Treatment Center. There is no Indian ATC at this time, and the practical model for Indian families is international travel to a qualified center in the UK, the EU, or Saudi Arabia where Casgevy is registered and the treating-center capability is established.

This is not a "ship the drug to India" case. It is a "route the family to the right treating center, coordinate the documentation, and carry the case end-to-end" case. Indian families have funded high-profile international gene-therapy treatments before, sometimes through ad-hoc crowdfunding campaigns. Reserve Meds positions as the documented, single-coordinator alternative to ad-hoc arrangements: one named coordinator, one case file, one chain of correspondence across what is typically a multi-city, multi-country coordination problem.

The CDSCO named-patient pathway for Casgevy

The legal foundation for personal import of unregistered medicines into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits import of small quantities of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application for the permit; Form 12B is the permit itself, issued by the office of the Drugs Controller General of India (DCGI) at FDA Bhawan in New Delhi, or by designated CDSCO Port Offices. Compassionate Use of drugs not approved for marketing in India is a parallel route filed by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient.

For Casgevy specifically, the regulatory question is shaped by the modality. The Form 12A pathway is sized for personal import of small-molecule and biologic products dispensed to the patient through a licensed facility. Casgevy is not dispensed to the patient in the conventional sense. It is the patient's own cells, collected by apheresis at the treating center, edited at the Vertex manufacturing facility, and returned to the same treating center for myeloablative conditioning and infusion. The cells do not travel to India unless the treating center is in India. As of this page's last review there is no Indian Authorized Treatment Center.

What this means operationally: for an Indian family pursuing Casgevy, the Rule 36 framework is relevant for ancillary materials sourced separately and for the broader documentation of the case for the patient's records and any India-side reimbursement attempts. The dominant access architecture is treating-center introduction at a UK MHRA, EMA, or SFDA jurisdiction with established Casgevy delivery capability. Reserve Meds carries the US-side sourcing relationship for ancillary materials where required, coordinates the patient-travel logistics, and prepares the documentation file in the Indian patient's name across the full multi-month treatment arc.

Where Rule 36 does come into the file is the post-treatment phase. Long-term hematologic monitoring and any imported reagents or supportive medicines used in India during the long follow-up window may require Rule 36 documentation. The treating physician in India, holding a valid National Medical Commission (NMC) registration number, signs the supporting prescription, and the application moves through CDSCO via the appropriate port office or the DCGI New Delhi office. CDSCO published guidance indicates that Form 12B permits issue on a priority basis, typically within one to two days for routine applications where the documentation is complete; in practice, families and institutions plan for a two to four week window from physician decision to dispensed material, because the elapsed time is upstream documentation assembly and downstream international logistics rather than the regulator's stamp.

The mandatory pre-treatment fertility preservation discussion is documented as a discrete element of the file. The busulfan myeloablative conditioning regimen carries a high risk of permanent infertility, and the fertility preservation discussion is not optional under any qualified treating center's protocol.

Where Casgevy gets delivered for Indian patients

The treating-center map for Casgevy is narrow because the combination of apheresis capacity, busulfan myeloablative conditioning experience, cryogenic cell-therapy infrastructure, and Vertex manufacturing-slot allocation is concentrated at a small set of institutions globally. For Indian families, the practical destinations are typically the United Kingdom (NHS managed-access centers), select EU member states, or the Kingdom of Saudi Arabia where SFDA approval and KFSH&RC capability have created a regional reference site.

On the India side, the institutions that handle named-patient and compassionate imports as established workflow, and that maintain the hematopoietic stem cell transplant and bone marrow transplant capability relevant to pre-treatment work-up and post-treatment follow-up, include All India Institute of Medical Sciences (AIIMS), New Delhi; Tata Memorial Centre, Mumbai; Christian Medical College (CMC), Vellore; Apollo Hospitals (Chennai, Delhi, Bangalore, Hyderabad); Fortis Healthcare (Fortis Memorial Research Institute Gurgaon, Mumbai, Bangalore); Medanta in Gurgaon; Kokilaben Dhirubhai Ambani Hospital in Mumbai; MGM Healthcare in Chennai; and Manipal Hospitals in Bangalore. AIIMS is a designated Centre of Excellence under the National Policy for Rare Diseases. CMC Vellore and Tata Memorial Centre have particular depth in hematology and cell therapy. As an Indian Authorized Treatment Center capability develops in the coming years, the architecture will evolve. The current model routes the treatment itself abroad while keeping pre- and post-treatment continuity at the Indian institution.

For families that span multiple cities, the coordination problem is real. A grandmother in Hyderabad, a hematologist at Tata Memorial in Mumbai, an adult child in Bangalore handling logistics, and a son in Dubai or London paying invoices is a common configuration. Reserve Meds' single named coordinator model is built for this pattern: one coordinator, one case file, regardless of how many cities the family touches.

Real cost picture for Casgevy in India

The Casgevy cost structure is dominated by the manufactured cell product itself. US wholesale acquisition cost (WAC) is approximately USD 2.2 million per patient for the single one-time infusion (Vertex stated list price at launch, widely reported), which converts at the USD/INR rate in the 94 to 95 range in May 2026 to approximately INR 20.7 to 20.9 crore. This figure covers the cell product only. It does not include apheresis, manufacturing logistics, busulfan conditioning hospitalization, the cell-therapy infusion suite, post-infusion inpatient stay with transfusion and antimicrobial support, fertility preservation, long-term follow-up, or any international travel and accommodation for the Indian family.

International logistics for the manufactured cell product between Vertex and the treating center (cryogenic vapor-phase liquid nitrogen shippers) add a defined surcharge in the USD 25,000 to 50,000 range, with customs and chain-of-custody documentation handled in parallel. For Indian families travelling to the UK, EU, or Saudi Arabia for treatment, additional travel and accommodation costs for the multi-month treatment arc are typical in the USD 40,000 to USD 120,000 range depending on destination, family configuration, and length of stay. The Reserve Meds concierge coordination fee is a separate line item, transparently itemised at the firm-quote stage.

Indian private insurance behavior at this price point is restrictive. Star Health, HDFC ERGO, ICICI Lombard, and Niva Bupa each handle cell and gene therapy on a case-by-case basis; none reimburse a multi-million-dollar one-time gene therapy as a standard line item. CGHS provides for life-saving medicines not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS) for central government employees and pensioners, with stricter Expert Committee review for drugs not approved by CDSCO. The National Policy for Rare Diseases 2021 provides one-time financial assistance under the Rashtriya Arogya Nidhi umbrella at a ceiling of INR 50 lakh per patient, which is meaningful but materially below the all-in cost of Casgevy. Cash-pay is the default operating posture for Reserve Meds-coordinated cases. Union Budget 2026-27 expanded the list of life-saving and rare-disease drugs eligible for customs duty exemption; HSN code applicability for any specific shipment is confirmed at the documentation stage.

Typical timeline for Casgevy

The regulatory layer in India for Rule 36 filings runs one to two days at CDSCO for routine applications with complete documentation; assembly of the upstream clinical justification and the downstream shipment plan typically extends the practical window to two to four weeks. For the Casgevy treatment itself, the dominant variable is the clinical timeline at the qualified treating center abroad. From treating-center acceptance through CD34+ mobilization and apheresis, cryopreserved transit to Vertex, manufacturing (several weeks at the Vertex facility), shipment of the edited product back to the treating center, myeloablative conditioning, infusion, and engraftment recovery, the active treatment arc is approximately six months to one year. Long-term follow-up extends multiple years through the post-marketing registry. There are no shortcuts on this timeline. The biology of mobilization, manufacturing, and engraftment sets the pace.

What your physician needs to provide

The clinical justification letter is the cornerstone of any Casgevy case file involving an Indian patient. The letter, signed by a treating hematologist holding an active NMC registration number with state council registration where required, addresses the patient's diagnosis with ICD-10 coding (D57.x for SCD or D56.x for TDT), disease severity (documented vaso-occlusive crisis history for SCD, or transfusion frequency, ferritin trajectory, and iron-overload markers for TDT), prior therapies attempted (hydroxyurea, voxelotor, chronic transfusion, iron chelation with deferasirox or deferiprone) with outcomes, and the clinical case for one-time gene-edited cell therapy.

The dosing reference is the FDA label minimum of 3 x 10^6 CD34+ cells per kilogram of body weight, delivered as a single intravenous infusion of the patient's own edited autologous CD34+ product. The monitoring plan covers the pre-apheresis baseline workup (bone marrow assessment, infection screen including HIV and hepatitis B and C, organ function evaluation, fertility preservation discussion), the inpatient myeloablative conditioning window, the profound cytopenia and engraftment recovery period with transfusion and antimicrobial support, and the long-term hematologic and safety follow-up per the Vertex registry.

The mandatory pre-treatment fertility preservation discussion is documented as a discrete element of the file, not buried in the broader narrative. The receiving treating institution abroad will not initiate the apheresis-to-conditioning arc without a documented fertility preservation discussion completed. Adverse event reporting through the Pharmacovigilance Programme of India (PvPI), coordinated by the Indian Pharmacopoeia Commission, applies for any imported ancillary materials and is referenced in the Reserve Meds documentation kit. The reporting obligation itself stays with the prescribing physician.

Common questions about Casgevy in India

Will Star Health, HDFC ERGO, ICICI Lombard, or Niva Bupa cover Casgevy? Each plan handles cell and gene therapy on a case-by-case basis. None of the major Indian private insurers reimburse a multi-million-dollar one-time gene therapy as a standard line item. Reserve Meds provides documentation that lets a payer evaluate; the claim itself is filed by the patient or institution. Cash-pay is the default operating posture.

Will CGHS, ESIC, or the National Policy for Rare Diseases ceiling cover this? CGHS provides for life-saving medicines not in the standard formulary to be considered case-by-case by an Expert Committee under Special DG (DGHS), with stricter constraints for drugs not approved by CDSCO. The Rashtriya Arogya Nidhi ceiling under NPRD 2021 is currently INR 50 lakh per patient, which is meaningful but well below the all-in Casgevy cost. Check eligibility with your scheme administrator before assuming coverage.

Can my child be treated in India? As of this page's last review, there is no Indian Authorized Treatment Center for Casgevy. The pre-treatment workup and post-treatment follow-up can be coordinated with an Indian tertiary institution (AIIMS, Tata Memorial, CMC Vellore, Apollo, Fortis, Medanta, Kokilaben, MGM, Manipal). The apheresis, manufacturing, conditioning, and infusion run at a qualified treating center abroad. As Indian cell-therapy infrastructure expands, this model will evolve.

Is fertility preservation really mandatory? Yes. The busulfan conditioning regimen carries a high risk of permanent infertility, and the fertility preservation discussion is part of pre-treatment eligibility at every qualified treating center. AIIMS, Tata Memorial, and other Indian Centres of Excellence have fertility preservation pathways that align with the international cell-therapy program.

Why Casgevy versus Lyfgenia? Casgevy uses CRISPR-Cas9 to edit BCL11A and reactivate fetal hemoglobin. Lyfgenia uses a lentiviral vector to add a modified beta-globin gene and carries an FDA boxed warning for hematologic malignancy that Casgevy does not. Casgevy is also approved for transfusion-dependent beta-thalassemia, which is high-prevalence in India; Lyfgenia is not approved for TDT. Casgevy carries broader international registration including UK, EU, and SFDA, which matters operationally for Indian families travelling for treatment. The clinical choice rests with the treating cell-therapy team.

Is this a legitimate alternative to crowdfunding? Yes. Reserve Meds is a US-based concierge coordinator with documented sourcing, documented chain of custody, single-coordinator continuity, and transparent line-item pricing. The architecture is built specifically for the Indian family pattern of cross-border coordination across multiple cities and currencies, as a documented alternative to ad-hoc arrangements.

Where Reserve Meds fits in Casgevy cases

Reserve Meds is a US-based concierge coordinator. For a Casgevy inquiry from an Indian family, the working unit is treating-center introduction at a qualified Authorized Treatment Center abroad, US-side manufacturer-direct logistics on any ancillary materials, documentation kit preparation for the India-side file including the Rule 36 reference and the PvPI reference, and continuous coordination through the multi-month treatment arc and into long-term follow-up. The clinical decisions remain with the treating hematology and cell-therapy team. The regulatory authority remains CDSCO on the India side and the corresponding authority on the treating-jurisdiction side. The cell-therapy delivery remains with the qualified treating center.

What Reserve Meds carries: identification of the qualified treating institution with manufacturing slot availability, preparation of the documentation kit including the mandatory fertility preservation discussion reference, coordination of cryogenic shipment logistics from the Vertex manufacturing site to the treating center, multi-city family coordination across India and the destination country, and a single named coordinator who stays with the family through apheresis, manufacturing, conditioning, infusion, and the long-term follow-up reorder cycle for ancillary materials. Reserved for you.

Next step

If your family is considering Casgevy for severe sickle cell disease or transfusion-dependent beta-thalassemia, the first step is a coordinated intake that confirms eligibility, identifies the appropriate treating jurisdiction, and produces a transparent firm quote. The waitlist request prefills the relevant context so the coordinator who reaches out is already oriented to your case.

Join the Casgevy waitlist

Reserved for you.